Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Share-based Compensation came in at $749000.0 in Q1 2026, down 82.2% YoY from $4.2 million in Q1 2025, and down 50.63% on a QoQ basis from $1.5 million in Q4 2025.
Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Share-based Compensation data on file, last reported at $749000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 82.2% year-over-year to $749000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 66.25% YoY) and the FY2025 annual result came in at $9.8 million, down 63.88% from the prior year.
- Share-based Compensation slipped to $749000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $14.1 million in Q2 2022 to a low of $93000.0 in Q1 2023.
- A 5-year average of $5.8 million and a median of $5.8 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 94.98% — and 2024, when it jumped 8929.03%.
- Tracing ATRA's Share-based Compensation over 5 years: stood at $14.0 million in 2022, then slipped by 20.54% to $11.1 million in 2023, then tumbled by 47.54% to $5.8 million in 2024, then plunged by 74.05% to $1.5 million in 2025, then tumbled by 50.63% to $749000.0 in 2026.
- The last three Share-based Compensation figures came in at $749000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | 394,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 394,000.00 |
| Jun 30, 2026 | 394,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 4.21 Mn |
| Mar 31, 2025 | 4.21 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Sep 30, 2024 | 6.42 Mn |
| Sep 30, 2024 | 6.42 Mn |
| Jun 30, 2024 | 6.34 Mn |
| Jun 30, 2024 | 6.34 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Mar 31, 2024 | 8.40 Mn |